var data={"title":"Eumycetoma","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Eumycetoma</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/eumycetoma/contributors\" class=\"contributor contributor_credentials\">Beatriz Bustamante, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/eumycetoma/contributors\" class=\"contributor contributor_credentials\">Pablo E Campos, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/eumycetoma/contributors\" class=\"contributor contributor_credentials\">Carol A Kauffman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/eumycetoma/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/eumycetoma/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 03, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Eumycetoma (&quot;mycotic mycetoma&quot;) is a chronic subcutaneous fungal infection of the skin and soft tissue, most often affecting the lower extremity (typically a single foot) [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/1\" class=\"abstract_t\">1</a>]. The disease has been included in the World Health Organization's list of neglected diseases [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/2\" class=\"abstract_t\">2</a>].</p><p>Eumycetoma is caused by at least 39 hyaline and pigmented species of molds. Filamentous higher bacteria can cause similar clinical manifestations (actinomycotic mycetoma or actinomycetoma); these organisms are discussed separately. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-nocardiosis#H10\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of nocardiosis&quot;, section on 'Mycetoma'</a>.)</p><p>Infection typically occurs following skin or subcutaneous tissue inoculation of conidia via a contaminated thorn or splinter. Eumycetomas are usually confined to subcutaneous tissues but can involve fascia, bone, and regional lymph nodes via contiguous dissemination [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/3\" class=\"abstract_t\">3</a>].</p><p>Issues related to epidemiology, pathogenesis, clinical manifestations, diagnosis, treatment, and prevention of eumycetoma will be reviewed here. Issues related to actinomycotic mycetoma caused by filamentous higher bacteria are discussed separately. (See <a href=\"topic.htm?path=treatment-of-nocardiosis\" class=\"medical medical_review\">&quot;Treatment of nocardiosis&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-nocardiosis\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of nocardiosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most cases of eumycetoma occur among individuals living in developing countries in tropical and subtropical regions, although cases have been reported worldwide (including in countries in temperate regions). Eumycetoma typically affects healthy adult men such as field laborers or farmers who work in rural areas and have frequent exposure to soil. The mean age is 33 but ranges from 8 to 68 years; pediatric cases are rare. The male to female ratio is about 3:1 to 5:1.</p><p>Eumycetoma among animals is rare but has been reported in horses, water buffalo, and dogs. There are no known cases of zoonotic or laboratory acquisition of eumycetomas, nor has person-to-person transmission been described.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The pathogenesis of eumycetoma infection is not fully understood. Many individuals are exposed to eumycetoma agents, but only a few develop the disease. Risk factors appear to include environmental exposure to pathogenic organisms, genetic predisposition to infection, and immunosuppression.</p><p>Eumycetoma begins with traumatic inoculation of the organism into cutaneous <span class=\"nowrap\">and/or</span> subcutaneous tissues. Trauma may be minor (due to thorns, splinters, or other objects), and patients may not recall a specific injury [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/4-6\" class=\"abstract_t\">4-6</a>].</p><p>In general, infection remains localized. Grains (colonies of infecting organisms) are deposited in infected tissues; free filaments do not develop. The grains are partially broken down via a neutrophil-mediated inflammatory reaction; their remains perpetuate an inflammatory response. An epithelioid granuloma develops via recruitment of macrophages and multinucleated giant cells, which clear dead neutrophils and grain fragments [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/7\" class=\"abstract_t\">7</a>]. The host produces cytokines and enzymes to degrade the chitin contained in grains of <em>Madurella mycetomatis</em>, the most common cause of eumycetoma [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/8\" class=\"abstract_t\">8</a>].</p><p>Genetic predisposition to development of eumycetoma or actinomycetoma may be an important factor in pathogenesis. In endemic areas, many individuals have antibodies to <em>M. mycetomatis</em>. It has been postulated that some individuals lack sufficient neutrophil function to clear the organism and thus develop disease [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/9\" class=\"abstract_t\">9</a>]. In addition, polymorphism in the gene for chitotriosidase that results in enzyme inactivity has been associated with increased risk for mycetoma [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/8\" class=\"abstract_t\">8</a>].</p><p>Although eumycetoma frequently develops in the absence of immunosuppression, a number of cases have been reported in immunocompromised patients. These include one case due to <em>Exophiala jeanselmei</em> in a patient with an idiopathic CD4+ T cell lymphocytopenia and another case due to <em>Madurella</em> spp in a patient with acute myeloid leukemia undergoing chemotherapy [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/10,11\" class=\"abstract_t\">10,11</a>]. Eumycetoma has also been described in solid organ transplant recipients; most had a good outcome with antifungal therapy <span class=\"nowrap\">and/or</span> surgical management despite immunosuppressive therapy [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/12-15\" class=\"abstract_t\">12-15</a>]. One series described both eumycetoma and actinomycetoma in association with diabetes (9 out of 26 cases) [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/16\" class=\"abstract_t\">16</a>].</p><p>The role of the immune response in the setting of eumycetoma is not fully understood. Some studies have described a reduction in cell-mediated immune response among patients with eumycetoma or actinomycetoma [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/17,18\" class=\"abstract_t\">17,18</a>]; another failed to demonstrate any immune alteration [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/19\" class=\"abstract_t\">19</a>]. The small number of participants in these studies and the mixing of eumycetoma and actinomycetoma cases preclude drawing definitive conclusions. </p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">MICROBIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Organisms capable of causing eumycetoma are distributed worldwide and include at least 39 hyaline and pigmented species of molds (<a href=\"image.htm?imageKey=ID%2F58060\" class=\"graphic graphic_table graphicRef58060 \">table 1</a>). The predominant pathogen is <em>M. mycetomatis</em>, which, along with <em>Trematosphaeria grisea </em>(formerly<em> Madurella grisea</em>), <em>Falciformispora senegalensis </em>(formerly<em> Leptosphaeria senegalensis</em>), and <em>Scedosporium apiospermum</em> species complex (formerly <em>Pseudallescheria boydii</em><span class=\"nowrap\">/<em>Scedosporium</span> apiospermum</em>)<em>,</em> are responsible for more than 90 percent of reported eumycetoma cases around the world (<a href=\"image.htm?imageKey=ID%2F61250\" class=\"graphic graphic_figure graphicRef61250 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/20\" class=\"abstract_t\">20</a>]. Eumycetoma agents are summarized in the table (<a href=\"image.htm?imageKey=ID%2F58060\" class=\"graphic graphic_table graphicRef58060 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/21-32\" class=\"abstract_t\">21-32</a>].</p><p>The local prevalence of specific pathogens is determined by ecological conditions including temperature, rainfall, type of soil, prevalent vegetation, and pollution [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/33\" class=\"abstract_t\">33</a>]. <em>M. mycetomatis</em> is common in arid zones [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/34\" class=\"abstract_t\">34</a>], whereas <em>S. apiospermum</em> species complex is common in temperate rainy areas [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/16,35\" class=\"abstract_t\">16,35</a>]. <em>S. apiospermum</em> species complex are also found more frequently in nitrogen-rich environments with organic pollution from human, poultry, and cattle manure [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/36\" class=\"abstract_t\">36</a>]. In Africa, <em>M. mycetomatis</em> and <em>F. senegalensis</em> are the most common pathogens; <em>T. grisea</em> and <em>S. apiospermum</em> species complex are less frequent pathogens. In South America, <em>T. grisea</em> is the most prevalent pathogen, followed by <em>M. mycetomatis</em> and <em>S. apiospermum</em> species complex. In North America, <em>S. apiospermum</em> species complex are the most prevalent pathogens, followed by <em>T. grisea</em>.</p><p>Soil is the natural reservoir for most of these agents. <em>M. mycetomatis</em>, <em>T. grisea</em>, <em>S. apiospermum</em> species complex, <em>Phialophora verrucosa</em>, and <em>Neotestudina</em> <em>rosatii</em> have been isolated from soil samples [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/37,38\" class=\"abstract_t\">37,38</a>]. It has been demonstrated that thorns serve as mechanical vectors only after they are contaminated with soil. This was illustrated in an evaluation of thorns in the Senegal River region; culprit organisms were demonstrated on fallen Acacia thorns but not on green thorns (eg, thorns not contaminated with soil) [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/39,40\" class=\"abstract_t\">39,40</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Laboratory features</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The causative agents of eumycetoma can be isolated in culture, growing as a mold with septate hyphae. Grains (colonies of the pathogenic organism) may be seen in the discharge material from a draining sinus tract (microscopically <span class=\"nowrap\">and/or</span> macroscopically), although, in some cases, they may be visible only by histopathological examination.</p><p>Eumycetoma grains may be black or white to yellow (slightly creamy to yellow grains). Black grains are produced exclusively by fungi; <em>M. mycetomatis</em> is the most common cause of black-grain eumycetoma. White to yellow grains may be produced by fungi causing eumycetoma or by bacteria causing actinomycetoma; <em>S. apiospermum</em> species complex are the most common causes of white-grain eumycetoma (<a href=\"image.htm?imageKey=ID%2F58060\" class=\"graphic graphic_table graphicRef58060 \">table 1</a>).</p><p>The grains of some species associated with eumycetoma have thickened fungal cell walls (including <em>S. apiospermum</em> species complex, <em>Fusarium</em> spp, <em>Acremonium killiense</em>, and <em>M. mycetomatis</em>) [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/41\" class=\"abstract_t\">41</a>]. Cell-wall thickening may be an important factor in the difficulties associated with obtaining cultures from grains and targeting organisms with antifungal drugs. It may also represent a defense mechanism against phagocytic cells.</p><p>Grain cement (composed in variable proportions by melanoproteins) strengthens the grain and protects cells from host antibodies, hydrolytic enzymes, and antifungal drugs [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/42\" class=\"abstract_t\">42</a>]. The role of melanin is not fully understood, although it has been linked to virulence and pathogenicity. Melanization appears to protect the organism from strong oxidants and azole drugs in vitro [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/43\" class=\"abstract_t\">43</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Eumycetoma is a chronic subcutaneous mycotic infection of the skin and soft tissue. Uncovered areas exposed to trauma are most commonly affected [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/44\" class=\"abstract_t\">44</a>]. The incubation period between inoculation and clinical manifestations is uncertain, and many patients may not recall a specific predisposing injury.</p><p>Eumycetoma most frequently involves the feet, followed by legs and hands (80, 7, and 6 percent, respectively) [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/45\" class=\"abstract_t\">45</a>]. Workers who carry vegetable matter over exposed areas of the back or abdomen are susceptible to eumycetoma in these regions [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/46\" class=\"abstract_t\">46</a>]. Less frequent sites include buttocks, forearms, the groin area, <span class=\"nowrap\">head/neck,</span> perineum, and testicles [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/4,16,45,47-50\" class=\"abstract_t\">4,16,45,47-50</a>]. The occurrence of multiple eumycetomas is rare and should prompt consideration of alternative diagnoses [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/51\" class=\"abstract_t\">51</a>].</p><p>The characteristic clinical triad includes tumor, sinus tracts, and macroscopic grains. Initially, lesions are painless and commence as slowly growing indurated subcutaneous nodules (<a href=\"image.htm?imageKey=ID%2F67717\" class=\"graphic graphic_picture graphicRef67717 \">picture 1</a>). Extension of lesions occurs due to nodular swelling and coalescence, forming large tumors that evolve into necrotic abscesses and draining sinus tracts (<a href=\"image.htm?imageKey=ID%2F59276\" class=\"graphic graphic_picture graphicRef59276 \">picture 2</a> and <a href=\"image.htm?imageKey=ID%2F69384\" class=\"graphic graphic_picture graphicRef69384 \">picture 3</a>). These may produce serosanguineous or purulent discharge containing macroscopic or microscopic grains [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/52\" class=\"abstract_t\">52</a>]. (See <a href=\"#H5\" class=\"local\">'Laboratory features'</a> above.)</p><p>Eumycetoma may extend beyond the skin and subcutaneous tissues to adjacent structures including muscle, bone, and lymphatic vessels. Bone involvement is more frequent in the setting of longstanding lesions [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/4,53\" class=\"abstract_t\">4,53</a>]. Lesions in areas with thin subcutaneous tissue (eg, feet, hands, and skull) are more likely to progress to bone involvement. Bone involvement indicates a poor prognosis and requires a longer course of therapy.</p><p>Eumycetoma lesions may evolve over months, years, or decades. In the absence of treatment, they may become deforming and disabling tumors (<a href=\"image.htm?imageKey=ID%2F54129\" class=\"graphic graphic_picture graphicRef54129 \">picture 4</a>). Other complications include fibrosis, ankylosis, and lymphedema caused by lymphatic obstruction. The presence of pain is often associated with secondary bacterial infection (commonly caused by <em>Staphylococcus aureus</em>). In one series, this was described as a complication of both eumycetoma and actinomycetoma in 66 percent of cases [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/54\" class=\"abstract_t\">54</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The presence of the characteristic triad of tumor, sinus tracts, and macroscopic grains is useful for establishing a clinical diagnosis of eumycetoma (<a href=\"image.htm?imageKey=ID%2F115024\" class=\"graphic graphic_picture graphicRef115024 \">picture 5</a>), actinomycetoma, or actinomycosis. Black grains definitely indicate a fungal etiology, making a diagnosis of eumycetoma, while white to yellow grains may indicate fungal or bacterial infection. In the absence of sinus tracts or macroscopic grains, a deep-abscess biopsy is needed to evaluate for presence of grains in the tissue. A fine-needle aspiration smear is useful for diagnosis of eumycetoma if hyphae may be visualized [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/55\" class=\"abstract_t\">55</a>].</p><p>Grains should be examined by microscopy using 20% potassium hydroxide solution to identify fungal structures (broad, septate, and branching hyphae with large swollen cells at the edge) (<a href=\"image.htm?imageKey=ID%2F67692\" class=\"graphic graphic_picture graphicRef67692 \">picture 6</a>). Gram staining may be used to demonstrate the presence of bacteria producing actinomycetoma or actinomycosis.</p><p>Grains and tissue from deep biopsies must be cultured for species identification. Culture specimens should be washed with sterile saline solution prior to inoculation onto Sabouraud dextrose agar medium (with and without <a href=\"topic.htm?path=chloramphenicol-drug-information\" class=\"drug drug_general\">chloramphenicol</a> and cycloheximide). To increase yield (for any fungus), tissue samples should be plated without grinding. Inoculated plates must be kept at room temperature and at 37&deg;C for six to eight weeks because some causative agents grow relatively slowly. Following successful isolation in culture, standard mycological techniques may be used to for identification of the causative agent.</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Histopathology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Histopathological findings of eumycetoma consist of a chronic granulomatous reaction with purulent center. Grains of different morphologies may be observed; characteristics of grains inside the tissue may vary depending on the specific etiology (<a href=\"image.htm?imageKey=ID%2F78858\" class=\"graphic graphic_picture graphicRef78858 \">picture 7</a> and <a href=\"image.htm?imageKey=ID%2F50368\" class=\"graphic graphic_picture graphicRef50368 \">picture 8</a>).</p><p>The histopathology evaluation should include hematoxylin and eosin as well as periodic acid-Schiff (PAS) or Gomori methenamine silver staining. Fungal structures (broad, septate, and branching hyphae with large swollen cells at the edge) may be seen; hyphae may be hyaline or pigmented. Grain cement may or may not be seen; if present, it may be compact or loose. These characteristics are useful for presumptive species identification but may not be used for definitive diagnosis:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Grains of <em>M. mycetomatis</em> are large, ranging from 0.5 to 3 mm, appear rounded, oval, or trilobed, and consist of intertwining hyphae embedded in interstitial brownish cement. Grains contain melanin, heavy metals, proteins, and lipids [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/56\" class=\"abstract_t\">56</a>] and could be of filamentous or vesicular types. Both types can be found in the same lesion. Brown septate and branched hyphae may be slightly more swollen in the periphery of a filamentous-type grain, while unusually large cells that look like vesicles predominate in the vesicular type.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The characteristic histopathology of eumycetoma due to <em>S. apiospermum</em> species complex consists of eosinophilic grains with a clearer central area, abundant swollen cells, and without cement.</p><p/><p>Specific fluorescent antibody reagents have been developed to detect and identify <em>S. apiospermum </em>species complex in tissues, providing a rapid and reliable method for diagnosing the infection [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/57\" class=\"abstract_t\">57</a>]. In addition, monoclonal antibodies against <em>Aspergillus</em> galactomannan have shown high sensitivity and specificity in identifying <em>Aspergillus</em> species in formalin-fixed tissues without cross-reactivity with other filamentous fungi [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/58,59\" class=\"abstract_t\">58,59</a>].</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Imaging</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Radiographic imaging is useful for determining the extent of disease, including soft tissue and bone involvement [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/60\" class=\"abstract_t\">60</a>]. Findings in the setting of eumycetoma include soft tissue swelling, osteoporosis, and osteolytic lesions (<a href=\"image.htm?imageKey=ID%2F69857\" class=\"graphic graphic_diagnosticimage graphicRef69857 \">image 1</a>) [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/61-63\" class=\"abstract_t\">61-63</a>].</p><p>Cavities in eumycetoma bone lesions tend to be few in number and &ge;1 cm in diameter, with well-defined margins; they are frequently filled with grains. In contrast, cavitary lesions due to bacterial pathogens tend to be smaller but more numerous [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/33,64\" class=\"abstract_t\">33,64</a>].</p><p>Computed tomography (CT) is more sensitive than conventional radiographs for assessing early bone involvement, although it is not as specific and sensitive as magnetic resonance imaging (MRI) for diagnosing mycetoma. MRI is helpful for the early diagnosis of mycetoma, even in absence of discharging sinuses, and for a better determination of severity and extension of soft tissue involvement [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/65\" class=\"abstract_t\">65</a>].</p><p>MRI demonstrating a &quot;dot-in-circle sign&quot; correlates with inflammatory granulomata-containing grains and surrounded by fibrous matrix (<a href=\"image.htm?imageKey=ID%2F77021\" class=\"graphic graphic_diagnosticimage graphicRef77021 \">image 2</a>) [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/66\" class=\"abstract_t\">66</a>]. This &quot;dot-in-circle sign&quot; (which is seen as multiple, small, round- to oval-shaped hyperintense lesions separated and surrounded by a low-signal intensity rim [circle] and a tiny, central, low-signal focus [dot]) and the presence of macro- and microabscesses on a background of a hypointense matrix are specific signs of both eumycetoma and actinomycetoma, regardless of the etiological agent. MRI is also useful for assessing the response to treatment, including reduction in the volume of inflammatory tissue, transformation of inflammatory changes into fibrotic tissue, and reduction of bone destruction [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/60,67\" class=\"abstract_t\">60,67</a>]. (See <a href=\"topic.htm?path=approach-to-imaging-modalities-in-the-setting-of-suspected-osteomyelitis\" class=\"medical medical_review\">&quot;Approach to imaging modalities in the setting of suspected osteomyelitis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Serology and molecular testing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is no standardized serological test for diagnosis of eumycetoma. In circumstances when macroscopic and microscopic features of the isolate are not sufficient for precise identification (due to absence of conidia or other distinctive structures), molecular techniques may be useful. The internal transcribed spacer region of ribosomal DNA sequencing allows the identification of different fungal species [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/21,68-70\" class=\"abstract_t\">21,68-70</a>].</p><p>Only molecular methods such as polymerase chain reaction and DNA sequencing allow identification of etiologic agents of eumycetoma to the species level. Rolling circle amplification (RCA) is a rapid and specific tool with utility for diagnosis of black-grain eumycetoma-causative agents (<em>Madurella fahalii</em>, <em>M. mycetomatis</em>, <em>Madurella pseudomycetomatis</em>, <em>Madurella tropicana</em>, <em>T. grisea</em>, <em>F. senegalensis</em>, <em>Falciformispora tompkinsii</em>, and <em>Medicopsis romeroi</em>); it has specificity of 100 percent with no cross reactivity or false results [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/71\" class=\"abstract_t\">71</a>]. RCA also has been used for identification of a rare black-grain mycetoma agent, <em>E. jeanselmei</em> [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/72\" class=\"abstract_t\">72</a>], and for identification of a white-grain eumycetoma agent, <em>Scedosporium boydii</em> [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/73\" class=\"abstract_t\">73</a>].</p><p class=\"headingAnchor\" id=\"H5841269\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of eumycetoma is variable depending on the stage of the lesion. In the setting of the characteristic clinical triad of tumor, sinus tracts, and macroscopic grains, eumycetoma may be presumed if actinomycosis, botryomycosis, and nocardiosis have been excluded. Granules can be present in all three entities; the infections may be distinguished based on Gram stain and culture. (See <a href=\"topic.htm?path=cervicofacial-actinomycosis\" class=\"medical medical_review\">&quot;Cervicofacial actinomycosis&quot;</a> and <a href=\"topic.htm?path=botryomycosis\" class=\"medical medical_review\">&quot;Botryomycosis&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-nocardiosis\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of nocardiosis&quot;</a>.)</p><p>The differential diagnosis of early eumycetoma includes:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Foreign body granuloma &ndash; A foreign body granuloma is a response of biologic material to foreign material in the tissue. The diagnosis may be established radiographically or via biopsy.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Soft tissue tumor &ndash; Soft tissue swelling may reflect a benign soft tissue tumor (such as a lipoma) or a malignant tumor (such as sarcoma, metastatic carcinoma, melanoma, or lymphoma). The diagnosis is established via biopsy. (See <a href=\"topic.htm?path=clinical-presentation-histopathology-diagnostic-evaluation-and-staging-of-soft-tissue-sarcoma\" class=\"medical medical_review\">&quot;Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cystic lesion &ndash; A cyst is a closed pocket of tissue that may be filled with fluid, pus, or other material. Epidermoid cysts are the most common cutaneous cysts; the diagnosis is usually based on the clinical appearance of a discrete nodule, often with a central punctum, that is freely movable on palpation. (See <a href=\"topic.htm?path=overview-of-benign-lesions-of-the-skin#H59809494\" class=\"medical medical_review\">&quot;Overview of benign lesions of the skin&quot;, section on 'Cysts'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Folliculitis &ndash; Folliculitis is a superficial infection of the hair follicles with purulent material in the epidermis. The diagnosis of folliculitis is based upon clinical manifestations. (See <a href=\"topic.htm?path=infectious-folliculitis\" class=\"medical medical_review\">&quot;Infectious folliculitis&quot;</a>.)</p><p/><p>The differential diagnosis of eumycetoma in the absence of sinus tracts or grains includes:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sporotrichosis &ndash; Sporotrichosis is a subacute to chronic infection caused by species from the <em>Sporothrix schenckii</em> complex. Infection usually involves cutaneous and subcutaneous tissues but can occasionally occur in other sites. The diagnosis is established via culture. (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-sporotrichosis\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of sporotrichosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chromoblastomycosis &ndash; Chromoblastomycosis is a subcutaneous fungal infection caused by one of several dematiaceous (pigmented) fungi. Examination of skin scrapings with potassium hydroxide (KOH) or skin biopsy demonstrates characteristic pigmented Medlar bodies, which are thick-walled structures 4 to 12 micrometers in diameter that are globe shaped and copper colored. Fungal culture allows species differentiation.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cutaneous leishmaniasis &ndash; Cutaneous leishmaniasis is a protozoal infection that produces skin ulcers. The diagnosis requires demonstration of the parasite in a clinical specimen (usually skin) by histology, culture, or molecular analysis via polymerase chain reaction. (See <a href=\"topic.htm?path=cutaneous-leishmaniasis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Cutaneous leishmaniasis: Clinical manifestations and diagnosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cutaneous tuberculosis &ndash; Tuberculosis is a mycobacterial infection that most frequently occurs due to infection with <em>Mycobacterium tuberculosis</em>, an acid-fast bacillus. Cutaneous tuberculosis may result from direct entry of the mycobacterium into the skin or from local or hematogenous spread of <em>M. tuberculosis</em> from an endogenous focus. (See <a href=\"topic.htm?path=cutaneous-manifestations-of-tuberculosis\" class=\"medical medical_review\">&quot;Cutaneous manifestations of tuberculosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Elephantiasis &ndash; Elephantiasis refers to severe lymphedema that occurs in the setting of filariasis, which is caused by nematodes (roundworms) that inhabit the lymphatics and subcutaneous tissues. The diagnosis is established via antigen testing <span class=\"nowrap\">and/or</span> blood smear examination. (See <a href=\"topic.htm?path=lymphatic-filariasis-epidemiology-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Lymphatic filariasis: Epidemiology, clinical manifestations, and diagnosis&quot;</a> and <a href=\"topic.htm?path=lymphatic-filariasis-treatment-and-prevention\" class=\"medical medical_review\">&quot;Lymphatic filariasis: Treatment and prevention&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Podoconiosis &ndash; Podoconiosis is an inflammatory reaction to mineral particles in certain soils that can result in lymphedema and elephantiasis. Podoconiosis occurs in the tropics at altitudes higher than those at which mosquitoes can transmit filarial infection (a maximum of about 1500 meters, or 4920 feet).</p><p/><p>Bone involvement should prompt consideration of:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bacterial osteomyelitis &ndash; Osteomyelitis is infection localized to bone. The diagnosis of osteomyelitis is established via isolation of bacteria from a bone biopsy sample together with histologic findings of inflammation and osteonecrosis. (See <a href=\"topic.htm?path=overview-of-osteomyelitis-in-adults\" class=\"medical medical_review\">&quot;Overview of osteomyelitis in adults&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Skeletal tuberculosis &ndash; Skeletal tuberculosis refers to tuberculous involvement of the bones <span class=\"nowrap\">and/or</span> joints. The diagnosis of musculoskeletal TB is established by microscopy and culture of infected material. (See <a href=\"topic.htm?path=skeletal-tuberculosis\" class=\"medical medical_review\">&quot;Skeletal tuberculosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Malignant bone tumor &ndash; Bone tumors include osteosarcoma, chondrosarcoma, Ewing sarcoma, and other tumors. The diagnosis is established via histopathology. (See <a href=\"topic.htm?path=bone-tumors-diagnosis-and-biopsy-techniques\" class=\"medical medical_review\">&quot;Bone tumors: Diagnosis and biopsy techniques&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of eumycetoma consists of prolonged drug therapy. The role of surgery is limited; if pursued, surgery should always be performed in conjunction with antifungal therapy.</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Antimicrobial therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For treatment of eumycetoma due to <em>M. mycetomatis</em>, <em>T. grisea,</em> or <em>F. senegalensis,</em> we favor <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> (200 mg orally twice daily). For treatment of eumycetoma due to <em>S. apiospermum </em>species complex, we favor <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> (loading dose 400 mg orally every 12 hours for the first 24 hours, followed by 200 mg twice daily; the dose may be increased to 300 mg twice daily if needed). Therapeutic alternatives include <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a> extended-release tablets (300 mg twice daily for the first day, then 300 mg daily) or posaconazole oral suspension (200 mg four times daily or 400 mg twice daily).</p><p>There are no prospective, randomized clinical trials to determine the most effective drug therapy for eumycetoma. Published reports mix both eumycetoma and actinomycetoma cases and do not differentiate between those with and without bone involvement. Therefore, the approach to management is based on few case reports with small numbers of patients with limited follow-up periods.</p><p>The causative agent should be identified prior to initiation of therapy, if feasible. In vitro susceptibility testing need not be performed routinely. Selection and duration of therapy must be tailored depending on individual patient circumstances, as in vitro susceptibility testing does not always predict the clinical response to therapy.</p><p>Antifungal therapy for eumycetoma should consist of azole antifungals; amphotericin B has not proven effective for long-term cure. The most useful agents are <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a>, <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a>, <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a>, and <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a>; there is limited information about <a href=\"topic.htm?path=isavuconazole-isavuconazonium-sulfate-drug-information\" class=\"drug drug_general\">isavuconazole</a>. <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">Fluconazole</a> is not adequate therapy for the treatment of eumycetoma because of intrinsic resistance. In vitro susceptibility of <em>M. mycetomatis</em> is high for ravuconazole, isavuconazole, and posaconazole, good for itraconazole and ketoconazole, poor for <a href=\"topic.htm?path=terbinafine-drug-information\" class=\"drug drug_general\">terbinafine</a>, and absent for the three echinocandins (<a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a>, <a href=\"topic.htm?path=anidulafungin-drug-information\" class=\"drug drug_general\">anidulafungin</a>, and <a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">micafungin</a>) [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/74-77\" class=\"abstract_t\">74-77</a>]. Similar results were found when other agents of black-grain eumycetoma were evaluated [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/78\" class=\"abstract_t\">78</a>].</p><p>The earliest studies of azoles for treatment of eumycetoma were performed with <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/16,79-81\" class=\"abstract_t\">16,79-81</a>]. In one study of 50 patients with <em>M. mycetomatis</em>, treatment with ketoconazole (200 mg twice daily) led to improvement or cure in 72 percent of cases (duration of therapy 9 to 36 months) [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/79\" class=\"abstract_t\">79</a>]. In general, likelihood for cure has appeared relatively favorable with ketoconazole treatment for &ge;6 months, but adverse drug events limit the long-term use of this agent [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/16,80\" class=\"abstract_t\">16,80</a>]. Ketoconazole should not be a first-line treatment for any fungal infection because it can cause severe liver injuries and adrenal gland problems and can produce harmful drug interactions. Ketoconazole should be used only when alternative antifungal therapies are not available or tolerated and the potential benefits outweigh the potential risks [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/82\" class=\"abstract_t\">82</a>].</p><p>Case reports have reported mixed success with use of <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a>, although this agent is better tolerated than <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/16,79,83,84\" class=\"abstract_t\">16,79,83,84</a>]. Among a small number of patients with <em>M. mycetomatis</em>, itraconazole (100 mg twice daily) led to improvement in 42 percent of cases [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/16\" class=\"abstract_t\">16</a>]. Itraconazole serum drug-level monitoring should be undertaken (if feasible), since absorption of itraconazole may be erratic. Monitoring should be performed after the steady state has been reached in about two weeks, and the goal is to maintain the serum level above 1 <span class=\"nowrap\">mcg/mL</span>. Itraconazole has also been used in a dose of 400 mg daily for three months, after which the dose was reduced to 200 mg daily for nine months. Clinical response to 400 mg daily was good, but the clinical response was slow when the dose was reduced to 200 mg daily. Posttreatment surgery showed lesions well localized, encapsulated with thick capsule, and easily removed in all patients; after a follow-up period ranging from 18 to 36 months, only one patient presented with recurrence [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/85\" class=\"abstract_t\">85</a>].</p><p>In cases of intolerance or refractoriness to <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a>, acceptable alternatives include <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> (dosing outlined below) or <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a> extended-release tablets (300 mg twice daily for the first day, then 300 mg daily) or posaconazole oral suspension (200 mg four times daily or 400 mg twice daily) [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/86\" class=\"abstract_t\">86</a>].</p><p><a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">Voriconazole</a> is the preferred agent for treatment of eumycetoma due to <em>S. apiospermum </em>species complex. Voriconazole has been used for the treatment of invasive infections due to these agents<em> </em>with good results, including severe forms or disseminated disease involving central nervous system and bone [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/87-94\" class=\"abstract_t\">87-94</a>]. Voriconazole therapy consists of a loading dose 400 mg orally every 12 hours for the first 24 hours, followed by 200 mg twice daily; the dose may be increased to 300 mg twice daily if needed. Voriconazole serum drug-level monitoring should be undertaken (if feasible) because serum levels can be highly variable. Monitoring should be performed after the steady state has been reached in about five to seven days, and the goal is to maintain the serum level between 1 to 5 <span class=\"nowrap\">mcg/mL</span> [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/95\" class=\"abstract_t\">95</a>]. Levels greater than 5 <span class=\"nowrap\">mcg/mL</span> are associated with increased toxicity.</p><p>In patients with eumycetoma refractory to standard antifungal therapy, <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a> (400 mg two times daily or 200 mg four times daily) has been associated with partial or complete response [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/86,96-98\" class=\"abstract_t\">86,96-98</a>].</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Surgery</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The role of surgery for management of eumycetoma is limited, since relapse rates after surgery are high. In one study including 1013 patients with eumycetoma due to <em>M. mycetomatis, </em>relapse occurred in 27 percent of cases [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/99\" class=\"abstract_t\">99</a>]. Risk factors for recurrence include disease duration, extra-pedal involvement, older age, previous surgical excision, family history of mycetoma, and residence in nonendemic area [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/99\" class=\"abstract_t\">99</a>].</p><p>If surgery is deemed warranted, it always should be performed in conjunction with administration of antifungal therapy prior to and following debridement. The use of antifungal drugs before surgery reduces the size of the tumor, and their use after surgery reduces the recurrence rate [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/100,101\" class=\"abstract_t\">100,101</a>]. At least six months of antifungal therapy should be administered prior to consideration of surgery [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/100\" class=\"abstract_t\">100</a>].</p><p>Surgery should be considered early in cases of small and well-demarcated lesions only, and a wide margin of healthy tissue must be excised [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/102\" class=\"abstract_t\">102</a>]. There is no utility for radical surgical procedures [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/64\" class=\"abstract_t\">64</a>]. Surgery is not warranted to remove grains or reduce pain and swelling caused by draining sinuses. Amputation may be considered only for those cases with severe, progressive disability; if needed, the goal of amputation should be to prevent further deterioration in quality of life.</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Follow-up</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The optimal duration of antimicrobial therapy for treatment of eumycetoma is uncertain and depends on individual circumstances. In general, at least 12 months of therapy is appropriate; treatment may be required for two years or more. Bone involvement indicates a poor prognosis and requires a longer course of therapy. Hepatic enzyme monitoring should be performed monthly during azole therapy.</p><p>Treatment should be continued for at least three months after a clinical and radiographic cure is achieved. Clinical signs of improvement include reduction in swelling, decreasing purulent discharge, closing of sinus tracts, reduction in pain, and improvement of mobility. Radiographic signs of improvement include resolution of signs indicative of active osteomyelitis. Patients should be followed for at least two years after discontinuation of antimicrobial therapy before declaring a cure [<a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/19\" class=\"abstract_t\">19</a>].</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h1\">PREVENTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Use of protective equipment including shoes and gloves should be promoted in the setting of contact with soil whenever possible. In addition, healthcare professionals working in endemic areas must be educated to recognize and treat eumycetoma promptly before progression to advanced disease.</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Eumycetoma is a chronic subcutaneous fungal infection of the skin and soft tissue, most often affecting the lower extremity. It is caused by more than 39 species of molds.(See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most cases of eumycetoma occur among individuals living in developing countries in tropical and subtropical regions, although cases have been reported worldwide. Eumycetoma most frequently involves the feet, followed by legs and hands, where exposure to contaminated soil occurs most commonly. (See <a href=\"#H2\" class=\"local\">'Epidemiology'</a> above and <a href=\"#H6\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Eumycetoma begins with traumatic inoculation of the organism into cutaneous <span class=\"nowrap\">and/or</span> subcutaneous tissues. Trauma may be minor (due to thorns, splinters, or other objects), and patients may not recall a specific injury. Grains (which are actual colonies of infecting organisms) are deposited in infected tissues and partially broken down via a neutrophil-mediated inflammatory reaction. Their remains perpetuate an inflammatory response. (See <a href=\"#H3\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Organisms capable of causing eumycetoma are distributed worldwide and include at least 30 hyaline and pigmented species of molds (<a href=\"image.htm?imageKey=ID%2F58060\" class=\"graphic graphic_table graphicRef58060 \">table 1</a>). The predominant pathogen is <em>Madurella mycetomatis</em>, which, along with <em>Trematosphaeria grisea</em>, <em>Falciformispora senegalensis</em>, and <em>Scedosporium apiospermum</em> species complex<em>,</em> are responsible for more than 90 percent of cases. (See <a href=\"#H4\" class=\"local\">'Microbiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Microbiology evaluation includes microscopic examination as well as culture of grains and deep biopsy specimens. Grains may be seen in the discharged material from a draining sinus tract (microscopically <span class=\"nowrap\">and/or</span> macroscopically), although, in some cases, they may be visible only by histopathological examination. (See <a href=\"#H5\" class=\"local\">'Laboratory features'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The presence of the characteristic triad of tumor, sinus tracts, and macroscopic grains is useful for establishing a clinical diagnosis of eumycetoma, actinomycosis, botryomycosis, and nocardiosis. Black grains definitely indicate a fungal etiology, establishing a diagnosis of eumycetoma, while white to yellow grains may indicate fungal or bacterial infection. In the absence of sinus tracts or macroscopic grains, a deep-abscess biopsy is needed to evaluate for presence of grains in the tissue. (See <a href=\"#H8\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For treatment of eumycetoma due to <em>M. mycetomatis</em>, <em>T. grisea</em>, or <em>F. senegalensis,</em> we suggest <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). For treatment of eumycetoma due to <em>S. apiospermum </em>species complex, we suggest <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">Posaconazole</a> seems to be a good alternative for refractory cases. (See <a href=\"#H12\" class=\"local\">'Treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The optimal duration of therapy for eumycetoma is uncertain and depends on individual circumstances. In general, at least 12 months of therapy is appropriate, but treatment may be required for two years or more. Patients who have eumycetoma should be followed for at least two years after end of treatment before declaring a cure. (See <a href=\"#H16\" class=\"local\">'Follow-up'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The role of surgery for management of eumycetoma is limited, since relapse rates after surgery are high. If surgery is deemed warranted, it always should be performed in conjunction with administration of antifungal therapy prior to and following debridement. (See <a href=\"#H15\" class=\"local\">'Surgery'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/1\" class=\"nounderline abstract_t\">Zijlstra EE, van de Sande WW, Welsh O, et al. Mycetoma: a unique neglected tropical disease. Lancet Infect Dis 2016; 16:100.</a></li><li class=\"breakAll\">World Health Organization. Addressing the burden of mycetoma, 28 May 2016. http://www.who.int/neglected_diseases/mediacentre/WHA_69.21_Eng.pdf?ua=1&amp;ua=1 (Accessed on August 31, 2017).</li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/3\" class=\"nounderline abstract_t\">el Hassan AM, Mahgoub ES. Lymph node involvement in mycetoma. Trans R Soc Trop Med Hyg 1972; 66:165.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/4\" class=\"nounderline abstract_t\">ABBOTT P. Mycetoma in the Sudan. Trans R Soc Trop Med Hyg 1956; 50:11.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/5\" class=\"nounderline abstract_t\">Yu AM, Zhao S, Nie LY. Mycetomas in northern Yemen: identification of causative organisms and epidemiologic considerations. Am J Trop Med Hyg 1993; 48:812.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/6\" class=\"nounderline abstract_t\">Lee MW, Kim JC, Choi JS, et al. Mycetoma caused by Acremonium falciforme: successful treatment with itraconazole. J Am Acad Dermatol 1995; 32:897.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/7\" class=\"nounderline abstract_t\">Fahal AH, el Toum EA, el Hassan AM, et al. The host tissue reaction to Madurella mycetomatis: new classification. J Med Vet Mycol 1995; 33:15.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/8\" class=\"nounderline abstract_t\">Verwer PE, Notenboom CC, Eadie K, et al. A Polymorphism in the Chitotriosidase Gene Associated with Risk of Mycetoma Due to Madurella mycetomatis Mycetoma--A Retrospective Study. PLoS Negl Trop Dis 2015; 9:e0004061.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/9\" class=\"nounderline abstract_t\">van de Sande WW, Fahal A, Verbrugh H, van Belkum A. Polymorphisms in genes involved in innate immunity predispose toward mycetoma susceptibility. J Immunol 2007; 179:3065.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/10\" class=\"nounderline abstract_t\">Neumeister B, Zollner TM, Krieger D, et al. Mycetoma due to Exophiala jeanselmei and Mycobacterium chelonae in a 73-year-old man with idiopathic CD4+ T lymphocytopenia. Mycoses 1995; 38:271.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/11\" class=\"nounderline abstract_t\">Satta R, Sanna S, Cottoni F. Madurella infection in an immunocompromised host. Int J Dermatol 2000; 39:939.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/12\" class=\"nounderline abstract_t\">Geyer AS, Fox LP, Husain S, et al. Acremonium mycetoma in a heart transplant recipient. J Am Acad Dermatol 2006; 55:1095.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/13\" class=\"nounderline abstract_t\">Meis JF, Schouten RA, Verweij PE, et al. Atypical presentation of Madurella mycetomatis mycetoma in a renal transplant patient. Transpl Infect Dis 2000; 2:96.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/14\" class=\"nounderline abstract_t\">O'Riordan E, Denton J, Taylor PM, et al. Madura foot in the U.K.: fungal osteomyelitis after renal transplantation. Transplantation 2002; 73:151.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/15\" class=\"nounderline abstract_t\">Van Etta LL, Peterson LR, Gerding DN. Acremonium falciforme (Cephalosporium falciforme) mycetoma in a renal transplant patient. Arch Dermatol 1983; 119:707.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/16\" class=\"nounderline abstract_t\">Hay RJ, Mahgoub ES, Leon G, et al. Mycetoma. J Med Vet Mycol 1992; 30 Suppl 1:41.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/17\" class=\"nounderline abstract_t\">Mahgoub ES, Gumaa SA, El Hassan AM. Immunological status of mycetoma patients. Bull Soc Pathol Exot Filiales 1977; 70:48.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/18\" class=\"nounderline abstract_t\">Nasr A, Abushouk A, Hamza A, et al. Th-1, Th-2 Cytokines Profile among Madurella mycetomatis Eumycetoma Patients. PLoS Negl Trop Dis 2016; 10:e0004862.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/19\" class=\"nounderline abstract_t\">Bendl BJ, Mackey D, Al-Saati F, et al. Mycetoma in Saudi Arabia. J Trop Med Hyg 1987; 90:51.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/20\" class=\"nounderline abstract_t\">van de Sande WW. Global burden of human mycetoma: a systematic review and meta-analysis. PLoS Negl Trop Dis 2013; 7:e2550.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/21\" class=\"nounderline abstract_t\">Hemashettar BM, Siddaramappa B, Munjunathaswamy BS, et al. Phaeoacremonium krajdenii, a cause of white grain eumycetoma. J Clin Microbiol 2006; 44:4619.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/22\" class=\"nounderline abstract_t\">Aguilar-Donis A, Torres-Guerrero E, Arenas-Guzm&aacute;n R, et al. Mycetoma caused by Phaeoacremonium parasiticum--a case confirmed with B-tubulin sequence analysis. Mycoses 2011; 54:e615.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/23\" class=\"nounderline abstract_t\">de Hoog GS, van Diepeningen AD, Mahgoub el-S, van de Sande WW. New species of Madurella, causative agents of black-grain mycetoma. J Clin Microbiol 2012; 50:988.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/24\" class=\"nounderline abstract_t\">Hashemi SJ, Nasrollahi A, Guerami M, et al. Mycetoma in Iran: study of 62 cases. Asian J Epidemiol 2008; 1:77.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/25\" class=\"nounderline abstract_t\">Iriart X, Binois R, Fior A, et al. Eumycetoma caused by Diaporthe phaseolorum (Phomopsis phaseoli): a case report and a mini-review of Diaporthe/Phomopsis spp invasive infections in humans. Clin Microbiol Infect 2011; 17:1492.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/26\" class=\"nounderline abstract_t\">Mhmoud NA, Ahmed SA, Fahal AH, et al. Pleurostomophora ochracea, a novel agent of human eumycetoma with yellow grains. J Clin Microbiol 2012; 50:2987.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/27\" class=\"nounderline abstract_t\">Motswaledi HM, Mathekga K, Sein PP, Nemutavhanani DL. Paecilomyces lilacinus eumycetoma. Int J Dermatol 2009; 48:858.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/28\" class=\"nounderline abstract_t\">Campos-Mac&iacute;as P, Arenas-Guzm&aacute;n R, Hern&aacute;ndez-Hern&aacute;ndez F. Fusarium subglutinans: A new eumycetoma agent. Med Mycol Case Rep 2013; 2:128.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/29\" class=\"nounderline abstract_t\">Borman AM, Desnos-Ollivier M, Campbell CK, et al. Novel Taxa Associated with Human Fungal Black-Grain Mycetomas: Emarellia grisea gen. nov., sp. nov., and Emarellia paragrisea sp. nov. J Clin Microbiol 2016; 54:1738.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/30\" class=\"nounderline abstract_t\">Ahmed SA, van de Sande WW, Stevens DA, et al. Revision of agents of black-grain eumycetoma in the order Pleosporales. Persoonia 2014; 33:141.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/31\" class=\"nounderline abstract_t\">Al-Hatmi AM, Bonifaz A, Tirado-S&aacute;nchez A, et al. Fusarium species causing eumycetoma: Report of two cases and comprehensive review of the literature. Mycoses 2017; 60:204.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/32\" class=\"nounderline abstract_t\">Bustamante B, Ahmed SA, De Hoog GS, et al. Phaeoacremonium sphinctrophorum as a Novel Agent of Eumycetoma. JAMA Dermatol 2016; 152:1063.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/33\" class=\"nounderline abstract_t\">Boiron P, Locci R, Goodfellow M, et al. Nocardia, nocardiosis and mycetoma. Med Mycol 1998; 36 Suppl 1:26.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/34\" class=\"nounderline abstract_t\">MARIAT F. [On the geographic distribution and incidence of mycetoma agents]. Bull Soc Pathol Exot Filiales 1963; 56:35.</a></li><li class=\"breakAll\">Mahgoub ES. Mycetoma. In: Tropical Mycoses, Mahgoub ES (Ed), Jansen Research Council, 1989. p.57.</li><li class=\"breakAll\">Rippon JW. Medical mycology: the pathogenic fungi and the pathogenic actinomycetes, 2nd ed, WB Saunders Co, Philadelphia 1982. p.596.</li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/37\" class=\"nounderline abstract_t\">Gezuele E, Mackinnon JE, Conti-D&iacute;az IA. The frequent isolation of Phialophora verrucosa and Phialophora pedrosoi from natural sources. Sabouraudia 1972; 10:266.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/38\" class=\"nounderline abstract_t\">Ahmed A, Adelmann D, Fahal A, et al. Environmental occurrence of Madurella mycetomatis, the major agent of human eumycetoma in Sudan. J Clin Microbiol 2002; 40:1031.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/39\" class=\"nounderline abstract_t\">Segretain G, Mariat F. [Research on the presence of agents of mycetoma in the soil and thorny plants of Senegal and Mauritania]. Bull Soc Pathol Exot Filiales 1968; 61:194.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/40\" class=\"nounderline abstract_t\">Segretain G. [Epidemiology of mycetomas]. Ann Soc Belg Med Trop 1972; 52:277.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/41\" class=\"nounderline abstract_t\">Hay RJ, Collins MJ. An ultrastructural study of pale eumycetoma grains. Sabouraudia 1983; 21:261.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/42\" class=\"nounderline abstract_t\">Findlay GH, Vismer HF. Black grain mycetoma. A study of the chemistry, formation and significance of the tissue grain in Madurella mycetomi infection. Br J Dermatol 1974; 91:297.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/43\" class=\"nounderline abstract_t\">van de Sande WW, de Kat J, Coppens J, et al. Melanin biosynthesis in Madurella mycetomatis and its effect on susceptibility to itraconazole and ketoconazole. Microbes Infect 2007; 9:1114.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/44\" class=\"nounderline abstract_t\">Maiti PK, Ray A, Bandyopadhyay S. Epidemiological aspects of mycetoma from a retrospective study of 264 cases in West Bengal. Trop Med Int Health 2002; 7:788.</a></li><li class=\"breakAll\">Bustamante B, Campos PE. Eumycetoma. In: Atlas of fungal infections, 2nd, Kauffman CA (Ed), Current Medicine LLC, 2007. p.203.</li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/46\" class=\"nounderline abstract_t\">L&oacute;pez Mart&iacute;nez R, M&eacute;ndez Tovar LJ, Lavalle P, et al. [Epidemiology of mycetoma in Mexico: study of 2105 cases]. Gac Med Mex 1992; 128:477.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/47\" class=\"nounderline abstract_t\">Soni N, Gupta A, Shekhawat NS. Mycetoma - an unusual site. Surgery 2000; 127:709.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/48\" class=\"nounderline abstract_t\">Ly F, Develoux M, Deme A, et al. [Tumoral mycetoma of the buttock]. Ann Dermatol Venereol 2000; 127:67.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/49\" class=\"nounderline abstract_t\">Gumaa SA, Satir AA, Shehata AH, Mahgoub ES. Tumor of the mandible caused by Madurella mycetomil. Am J Trop Med Hyg 1975; 24:471.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/50\" class=\"nounderline abstract_t\">Arbab MA, el Hag IA, Abdul Gadir AF, Siddik H el-R . Intraspinal mycetoma: report of two cases. Am J Trop Med Hyg 1997; 56:27.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/51\" class=\"nounderline abstract_t\">Fahal AH, el Hassan AM, Abdelalla AO, Sheik HE. Cystic mycetoma: an unusual clinical presentation of Madurella mycetomatis infection. Trans R Soc Trop Med Hyg 1998; 92:66.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/52\" class=\"nounderline abstract_t\">Hazra B, Bandyopadhyay S, Saha SK, et al. A study of mycetoma in eastern India. J Commun Dis 1998; 30:7.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/53\" class=\"nounderline abstract_t\">Castro LG, Belda J&uacute;nior W, Salebian A, Cuc&eacute; LC. Mycetoma: a retrospective study of 41 cases seen in S&atilde;o Paulo, Brazil, from 1978 to 1989. Mycoses 1993; 36:89.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/54\" class=\"nounderline abstract_t\">Ahmed AO, Abugroun ES. Unexpected high prevalence of secondary bacterial infection in patients with mycetoma. J Clin Microbiol 1998; 36:850.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/55\" class=\"nounderline abstract_t\">Gabhane SK, Gangane N, Anshu . Cytodiagnosis of eumycotic mycetoma: a case report. Acta Cytol 2008; 52:354.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/56\" class=\"nounderline abstract_t\">Ibrahim AI, El Hassan AM, Fahal A, van de Sande WW. A histopathological exploration of the Madurella mycetomatis grain. PLoS One 2013; 8:e57774.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/57\" class=\"nounderline abstract_t\">Jackson JA, Kaplan W, Kaufman L, Standard P. Development of fluorescent-antibody reagents for demonstration of Pseudallescheria boydii in tissues. J Clin Microbiol 1983; 18:668.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/58\" class=\"nounderline abstract_t\">Choi JK, Mauger J, McGowan KL. Immunohistochemical detection of Aspergillus species in pediatric tissue samples. Am J Clin Pathol 2004; 121:18.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/59\" class=\"nounderline abstract_t\">Fenelon LE, Hamilton AJ, Figueroa JI, et al. Production of specific monoclonal antibodies to Aspergillus species and their use in immunohistochemical identification of aspergillosis. J Clin Microbiol 1999; 37:1221.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/60\" class=\"nounderline abstract_t\">Czechowski J, Nork M, Haas D, et al. MR and other imaging methods in the investigation of mycetomas. Acta Radiol 2001; 42:24.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/61\" class=\"nounderline abstract_t\">Al-Ali AA, Kashgari TQ, Nathani PG, Moawad MK. Radiological manifestations of madura foot in the Eastern Province of Saudi Arabia. Ann Saudi Med 1997; 17:298.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/62\" class=\"nounderline abstract_t\">Abd Bagi ME, Fahal AH, Sheik HE, et al. Pathological fractures in mycetoma. Trans R Soc Trop Med Hyg 2003; 97:582.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/63\" class=\"nounderline abstract_t\">Tomimori-Yamashita J, Ogawa MM, Hirata SH, et al. Mycetoma caused by Fusarium solani with osteolytic lesions on the hand: case report. Mycopathologia 2002; 153:11.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/64\" class=\"nounderline abstract_t\">McGinnis MR. Mycetoma. Dermatol Clin 1996; 14:97.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/65\" class=\"nounderline abstract_t\">El Shamy ME, Fahal AH, Shakir MY, Homeida MM. New MRI grading system for the diagnosis and management of mycetoma. Trans R Soc Trop Med Hyg 2012; 106:738.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/66\" class=\"nounderline abstract_t\">Sarris I, Berendt AR, Athanasous N, et al. MRI of mycetoma of the foot: two cases demonstrating the dot-in-circle sign. Skeletal Radiol 2003; 32:179.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/67\" class=\"nounderline abstract_t\">Sharif HS, Clark DC, Aabed MY, et al. Mycetoma: comparison of MR imaging with CT. Radiology 1991; 178:865.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/68\" class=\"nounderline abstract_t\">Ahmed A, van de Sande W, Verbrugh H, et al. Madurella mycetomatis strains from mycetoma lesions in Sudanese patients are clonal. J Clin Microbiol 2003; 41:4537.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/69\" class=\"nounderline abstract_t\">Loulergue P, Hot A, Dannaoui E, et al. Successful treatment of black-grain mycetoma with voriconazole. Am J Trop Med Hyg 2006; 75:1106.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/70\" class=\"nounderline abstract_t\">Desnos-Ollivier M, Bretagne S, Dromer F, et al. Molecular identification of black-grain mycetoma agents. J Clin Microbiol 2006; 44:3517.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/71\" class=\"nounderline abstract_t\">Ahmed SA, van den Ende BH, Fahal AH, et al. Rapid identification of black grain eumycetoma causative agents using rolling circle amplification. PLoS Negl Trop Dis 2014; 8:e3368.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/72\" class=\"nounderline abstract_t\">Najafzadeh MJ, Dolatabadi S, Saradeghi Keisari M, et al. Detection and identification of opportunistic Exophiala species using the rolling circle amplification of ribosomal internal transcribed spacers. J Microbiol Methods 2013; 94:338.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/73\" class=\"nounderline abstract_t\">Lackner M, Najafzadeh MJ, Sun J, et al. Rapid identification of Pseudallescheria and Scedosporium strains by using rolling circle amplification. Appl Environ Microbiol 2012; 78:126.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/74\" class=\"nounderline abstract_t\">Ahmed SA, Kloezen W, Duncanson F, et al. Madurella mycetomatis is highly susceptible to ravuconazole. PLoS Negl Trop Dis 2014; 8:e2942.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/75\" class=\"nounderline abstract_t\">van Belkum A, Fahal AH, van de Sande WW. In vitro susceptibility of Madurella mycetomatis to posaconazole and terbinafine. Antimicrob Agents Chemother 2011; 55:1771.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/76\" class=\"nounderline abstract_t\">van de Sande WW, Fahal AH, Bakker-Woudenberg IA, van Belkum A. Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents. Antimicrob Agents Chemother 2010; 54:2738.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/77\" class=\"nounderline abstract_t\">Kloezen W, Meis JF, Curfs-Breuker I, et al. In vitro antifungal activity of isavuconazole against Madurella mycetomatis. Antimicrob Agents Chemother 2012; 56:6054.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/78\" class=\"nounderline abstract_t\">Ahmed SA, de Hoog GS, Stevens DA, et al. In vitro antifungal susceptibility of coelomycete agents of black grain eumycetoma to eight antifungals. Med Mycol 2015; 53:295.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/79\" class=\"nounderline abstract_t\">Welsh O, Salinas MC, Rodr&iacute;guez MA. Treatment of eumycetoma and actinomycetoma. Curr Top Med Mycol 1995; 6:47.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/80\" class=\"nounderline abstract_t\">Mahgoub ES, Gumaa SA. Ketoconazole in the treatment of eumycetoma due to Madurella mycetomii. Trans R Soc Trop Med Hyg 1984; 78:376.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/81\" class=\"nounderline abstract_t\">Venugopal PV, Venugopal TV, Ramakrishna ES, Ilavarasi S. Antimycotic susceptibility testing of agents of black grain eumycetoma. J Med Vet Mycol 1993; 31:161.</a></li><li class=\"breakAll\">US Food and Drug Administration. &quot;FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems.&quot; http://www.fda.gov/drugs/drugsafety/ucm362415.htm (Accessed on August 21, 2014).</li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/83\" class=\"nounderline abstract_t\">Resnik BI, Burdick AE. Improvement of eumycetoma with itraconazole. J Am Acad Dermatol 1995; 33:917.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/84\" class=\"nounderline abstract_t\">Smith EL, Kutbi S. Improvement of eumycetoma with itraconazole. J Am Acad Dermatol 1997; 36:279.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/85\" class=\"nounderline abstract_t\">Fahal AH, Rahman IA, El-Hassan AM, et al. The safety and efficacy of itraconazole for the treatment of patients with eumycetoma due to Madurella mycetomatis. Trans R Soc Trop Med Hyg 2011; 105:127.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/86\" class=\"nounderline abstract_t\">Negroni R, Tob&oacute;n A, Bustamante B, et al. Posaconazole treatment of refractory eumycetoma and chromoblastomycosis. Rev Inst Med Trop Sao Paulo 2005; 47:339.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/87\" class=\"nounderline abstract_t\">McGinnis MR, Pasarell L. In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications. J Clin Microbiol 1998; 36:2353.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/88\" class=\"nounderline abstract_t\">Nesky MA, McDougal EC, Peacock Jr JE. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis. Clin Infect Dis 2000; 31:673.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/89\" class=\"nounderline abstract_t\">Mu&ntilde;oz P, Mar&iacute;n M, Tornero P, et al. Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy. Clin Infect Dis 2000; 31:1499.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/90\" class=\"nounderline abstract_t\">Porte L, Khatibi S, Hajj LE, et al. Scedosporium apiospermum mycetoma with bone involvement successfully treated with voriconazole. Trans R Soc Trop Med Hyg 2006; 100:891.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/91\" class=\"nounderline abstract_t\">Troke P, Aguirrebengoa K, Arteaga C, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother 2008; 52:1743.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/92\" class=\"nounderline abstract_t\">Lexier R, Walmsley SL. Successful treatment of Madura foot caused by Pseudallescheria boydii with Escherichia coli superinfection: a case report. Can J Surg 1999; 42:307.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/93\" class=\"nounderline abstract_t\">Turner PG. Madura foot or plantar fibromatosis. J Bone Joint Surg Br 1989; 71:531.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/94\" class=\"nounderline abstract_t\">Schaenman JM, DiGiulio DB, Mirels LF, et al. Scedosporium apiospermum soft tissue infection successfully treated with voriconazole: potential pitfalls in the transition from intravenous to oral therapy. J Clin Microbiol 2005; 43:973.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/95\" class=\"nounderline abstract_t\">Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009; 53:24.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/96\" class=\"nounderline abstract_t\">Sharma AM, Sharma N, Nat A, et al. Case report: Non-invasive management of Madura foot with oral posaconazole and ciprofloxacin. Am J Trop Med Hyg 2014; 91:1259.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/97\" class=\"nounderline abstract_t\">Difonzo EM, Massi D, Vanzi L, et al. Madurella mycetomatis mycetoma treated successfully with oral posaconazole. J Chemother 2011; 23:243.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/98\" class=\"nounderline abstract_t\">Crabol Y, Poiree S, Bougnoux ME, et al. Last generation triazoles for imported eumycetoma in eleven consecutive adults. PLoS Negl Trop Dis 2014; 8:e3232.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/99\" class=\"nounderline abstract_t\">Wadal A, Elhassan TA, Zein HA, et al. Predictors of Post-operative Mycetoma Recurrence Using Machine-Learning Algorithms: The Mycetoma Research Center Experience. PLoS Negl Trop Dis 2016; 10:e0005007.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/100\" class=\"nounderline abstract_t\">Welsh O. Mycetoma. Current concepts in treatment. Int J Dermatol 1991; 30:387.</a></li><li><a href=\"https://www.uptodate.com/contents/eumycetoma/abstract/101\" class=\"nounderline abstract_t\">Mahgoub ES. Mycetoma. Semin Dermatol 1985; 4:230.</a></li><li class=\"breakAll\">Kwon-Chung KJ, Bennett JE. Mycetoma. In: Medical Mycology, Lea &amp; Febiger, Philadelphia 1992. p.560.</li></ol></div><div id=\"topicVersionRevision\">Topic 2439 Version 15.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H18\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">PATHOGENESIS</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">MICROBIOLOGY</a><ul><li><a href=\"#H5\" id=\"outline-link-H5\">Laboratory features</a></li></ul></li><li><a href=\"#H6\" id=\"outline-link-H6\">CLINICAL MANIFESTATIONS</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">DIAGNOSIS</a><ul><li><a href=\"#H9\" id=\"outline-link-H9\">Histopathology</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Imaging</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Serology and molecular testing</a></li></ul></li><li><a href=\"#H5841269\" id=\"outline-link-H5841269\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">TREATMENT</a><ul><li><a href=\"#H13\" id=\"outline-link-H13\">Antimicrobial therapy</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">Surgery</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">Follow-up</a></li></ul></li><li><a href=\"#H17\" id=\"outline-link-H17\">PREVENTION</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/2439|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=ID/69857\" class=\"graphic graphic_diagnosticimage\">- Eumycetoma with cavities</a></li><li><a href=\"image.htm?imageKey=ID/77021\" class=\"graphic graphic_diagnosticimage\">- Eumycetoma after treatment</a></li></ul></li><li><div id=\"ID/2439|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/61250\" class=\"graphic graphic_figure\">- Relative incidence eumycetoma organisms</a></li></ul></li><li><div id=\"ID/2439|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/67717\" class=\"graphic graphic_picture\">- Small mycetoma lesion A</a></li><li><a href=\"image.htm?imageKey=ID/59276\" class=\"graphic graphic_picture\">- Small mycetoma lesion B</a></li><li><a href=\"image.htm?imageKey=ID/69384\" class=\"graphic graphic_picture\">- Eumycetoma foot A</a></li><li><a href=\"image.htm?imageKey=ID/54129\" class=\"graphic graphic_picture\">- Eumycetoma foot B</a></li><li><a href=\"image.htm?imageKey=ID/115024\" class=\"graphic graphic_picture\">- Eumycetoma: Black grain</a></li><li><a href=\"image.htm?imageKey=ID/67692\" class=\"graphic graphic_picture\">- Black grain direct exam</a></li><li><a href=\"image.htm?imageKey=ID/78858\" class=\"graphic graphic_picture\">- Black grain histopathology</a></li><li><a href=\"image.htm?imageKey=ID/50368\" class=\"graphic graphic_picture\">- M mycetomatis skin biopsy</a></li></ul></li><li><div id=\"ID/2439|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/58060\" class=\"graphic graphic_table\">- Organisms that cause eumycetoma</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-imaging-modalities-in-the-setting-of-suspected-osteomyelitis\" class=\"medical medical_review\">Approach to imaging modalities in the setting of suspected osteomyelitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bone-tumors-diagnosis-and-biopsy-techniques\" class=\"medical medical_review\">Bone tumors: Diagnosis and biopsy techniques</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=botryomycosis\" class=\"medical medical_review\">Botryomycosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cervicofacial-actinomycosis\" class=\"medical medical_review\">Cervicofacial actinomycosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-sporotrichosis\" class=\"medical medical_review\">Clinical features and diagnosis of sporotrichosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-nocardiosis\" class=\"medical medical_review\">Clinical manifestations and diagnosis of nocardiosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-histopathology-diagnostic-evaluation-and-staging-of-soft-tissue-sarcoma\" class=\"medical medical_review\">Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-leishmaniasis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Cutaneous leishmaniasis: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-manifestations-of-tuberculosis\" class=\"medical medical_review\">Cutaneous manifestations of tuberculosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infectious-folliculitis\" class=\"medical medical_review\">Infectious folliculitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lymphatic-filariasis-epidemiology-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Lymphatic filariasis: Epidemiology, clinical manifestations, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lymphatic-filariasis-treatment-and-prevention\" class=\"medical medical_review\">Lymphatic filariasis: Treatment and prevention</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-benign-lesions-of-the-skin\" class=\"medical medical_review\">Overview of benign lesions of the skin</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-osteomyelitis-in-adults\" class=\"medical medical_review\">Overview of osteomyelitis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=skeletal-tuberculosis\" class=\"medical medical_review\">Skeletal tuberculosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-nocardiosis\" class=\"medical medical_review\">Treatment of nocardiosis</a></li></ul></div></div>","javascript":null}